Q-omics provides the consensus-scored CCSER2 profile across patient tissues and cancer cell-line models. CCSER2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCSER2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, CCSER2 RNA expression shows 21,038 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where CCSER2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCSER2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCSER2 survival associations across molecular data types. CCSER2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCSER2 RNA expression–survival associations across cancer types. High CCSER2 expression shows unfavorable associations in BLCA and ACC, but favorable associations in KIRC, SKCM, LGG and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCSER2 RNA expression.
This table summarizes CCSER2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CCSER2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCSER2 shows lower tumor expression in THCA, BLCA, LUSC, BRCA and KICH and higher tumor expression in LIHC. The THCA box plot shows higher CCSER2 RNA expression in normal versus tumor tissue (log2 FC = −0.660, t-test p < 0.001).
This table shows molecular features associated with CCSER2 in patient tissues and cancer cell lines. In patient samples, CCSER2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCSER2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
